Why Workflow Integration is the Critical Moat in MedTech

• The Context: Global healthcare providers, particularly in the US, are overwhelmed by data but starved for time. The challenge has shifted from data generation to data utility.

• The Lifecycle: Clinical innovation must transition from a standalone tool to a system-wide asset to reach the value inflection points required for institutional scale.

• The Balance: Technical accuracy provides the spark, but workflow integration creates the clinical moat that secures adoption and leads to acquisition.

• The Commercial Moat: Evaluating a startup is no longer just about the efficacy of a sensor; it is about how that innovation fits into the existing rhythm of a high-pressure clinical environment.

• The Strategy: Success is defined by building a repeatable, sticky business model that prioritizes the clinician’s time as much as the patient’s outcome.

• The Goal: We look for founders who solve for Ambient Administration and physician burnout, creating assets that are seen as indispensable by global strategic partners.

---

Beyond the Device: Why Workflow Integration is the Critical Moat in MedTech

Building a healthcare company requires more than just a breakthrough sensor or a precise algorithm. In the current global landscape, the challenge has shifted from data generation to data utility.

MedTech companies follow a specific lifecycle where clinical efficacy provides the foundation, but workflow harmony determines survival. At One Six 8 Ventures, we have observed that the technologies achieving sustainable adoption across global markets are those that prioritize the last mile of healthcare: the seamless integration into a clinician’s daily rhythm.

The Foundation: Technical Data Meets Workflow Logic

Founders often begin with a specific pillar of technical expertise. In MedTech, this is usually a defensible technological moat or a deep understanding of a clinical gap. However, technical enthusiasm alone will not secure institutional capital for the long haul.

To transform an invention into a viable business, the founding team must evolve. A sophisticated winning capability requires a story that combines clinical brilliance with a commercial strategy that understands the Total Cost of Care. In the US and other major markets, if a tool requires extensive new training or specialized IT support, that friction becomes a budget barrier. We look for founders who realize that a product is only as good as its ease of use within a high-pressure environment.

The Regulatory Speed Bump: Integration as a Compliance Asset

A common pitfall for expanding startups is viewing regulatory approval and commercial integration as separate hurdles. In 2026, the FDA and global regulators have placed increased scrutiny on how digital health tools and AI-driven devices interact with existing systems.

As the FDA faces resource constraints and longer review cycles for innovative devices, well-constructed submissions that account for system interoperability (such as HL7 or FHIR standards) are moving through the pipeline more smoothly. A founder who can demonstrate that their device does not create a data silo but instead feeds into the hospital’s EMR (Electronic Medical Record) is seen as a lower-risk bet. Cybersecurity readiness, including SOC 2 or HITRUST certification, is no longer optional, it is a prerequisite for any device that intends to touch a hospital network.

The Commercial Moat: CAC and Real-World Sales Metrics

When moving into commercialization, many founders struggle with identifying the right benchmarks for Customer Acquisition Cost (CAC). In MedTech, especially in surgical or capital equipment, there is no one-size-fits-all CAC. The complexity of the product and the intensity of training vary too widely for generic benchmarks.

Instead of chasing broad industry averages, we recommend focusing on a specific set of commercial metrics that sophisticated investors and agents actually trust:

• Cost to First Procedure: The real investment required to move a clinician from initial interest to an active user.

• Cost to Steady-State Utilization: The resources spent moving an account from a pilot phase to consistent, high-volume adoption.

• Sales Cycle Velocity: The precise timeframe from the first demonstration to the first live case.

The US Market Shift: The Rise of Ambulatory Surgery Centers (ASCs)

One of the most significant shifts in US healthcare is the migration of high-acuity procedures from hospital settings to Ambulatory Surgery Centers (ASCs). Recent CMS (Centers for Medicare & Medicaid Services) rules have added hundreds of procedures to the approved ASC list, including cardiac catheter ablations and spine surgeries.

For a MedTech startup, this means your technology must be portable, cost-effective, and easy to set up. ASCs operate on tighter margins and smaller staffs than major hospital networks. A device that requires a dedicated technician or hours of calibration will not survive in an ASC environment. We seek founders who are building for this decentralized reality, where the workflow isn't just about the surgery, it's about the rapid turnover of the operating room.

Designing for Stickiness: The Repeatable Scale Strategy

One of the most significant risks for early-stage investors is a team that has not stress-tested their tool in a real-world setting. Winning teams design for repeatability. A matured commercial partner or acquirer is rarely buying your current revenue; they are buying the strength of your business model.

Scale is achieved when a technology creates sticky accounts through workflow integration, procedural standardization, and ongoing service. To reach venture scale, founders must provide a clear, repeatable playbook that demonstrates how to win an account and then replicate that win across entire health systems.

The ROI of Physician Burnout: Solving the $5 Trillion Problem

The Human Factor is the most overlooked metric in MedTech valuation. With physician shortages expected to double by 2037, healthcare systems are at a breaking point. Labor and infrastructure now account for roughly 65% of all healthcare spending.

Technologies that solve for Ambient Administration, using AI or automated workflows to handle documentation and coding, are seeing the highest retention rates. When we evaluate an investment, we ask: Does this tool give the physician time back? If a diagnostic tool has 99% accuracy but adds five minutes of paperwork, it is a liability. If it has 95% accuracy but automates the charting process, it is a category-winning asset.

The Alignment Test: Bridging the Gap Between Sales and Clinical Success

To drive this repeatability, the commercial strategy must mirror the clinician's journey. Rather than focusing solely on top-line revenue, high-growth companies align their commercial milestones with clinical adoption.

This means prioritizing account acquisition and the successful execution of early cases, followed by site-wide rollouts. When commercial goals are tied to these clinical benchmarks, it ensures the team is focused on long-term utilization rather than just a one-time sale. This alignment is what transforms a product into an industry standard.

The Outcome: Why Workflow Wins the Exit

The team must be aligned on the magnitude of the outcome. MedTech is a high-risk asset class, and investors seek companies built to play in the big leagues. Workflow-integrated companies represent a more resilient investment because:

• Higher Retention: Once a tool is woven into the daily habit of a hospital, it becomes indispensable.

• Shorter Sales Cycles: Demonstrating a reduction in administrative burden is a powerful value proposition for hospital administrators and payers.

• Strategic Value: Integrated platforms are significantly more attractive to global MedTech acquirers looking to strengthen their existing digital ecosystems.

Building the Resilient Engine

A successful MedTech team is defined by its ability to execute within the messy reality of healthcare. It requires technical skill to build a moat, business acumen to validate the market, and strategic foresight to design for an exit. When you combine these elements, you move beyond the churn of survival and build a resilient engine capable of reaching the only finish line that matters: a successful exit.

---

If you are an investor interested in the MedTech sector and would like to learn more about our specific investment strategy and operator-led approach, or a founder developing next-generation technology, connect with our team to explore how operator-led experience can support your path to market success.

Build Your Team: What MedTech Investors & Acquirers Demand

• Building a company requires constructing a vehicle capable of navigating the Valley of Death.
  MedTech companies follow a specific lifecycle requiring rigorous growth to a value inflection point, often followed by amplification through strategic acquisition or public listing.

• Technical expertise provides the spark, but commercial balance determines survival.
  A sophisticated winning capability combines clinical brilliance, technical mastery, and commercial expertise that understands you're building an asset for acquisition, not just a product.

• The inner circle must demonstrate alignment through commitment, not just diversity of opinion.
  Healthy boardsboards and management team offer rigorous debate, but stakeholders with personal agendas, passive engagement, or misaligned timelines drain energy and require immediate correction.

• Founders with conviction outperform polished executives hired for fundraising.
  Investors need leaders who are all in financially, emotionally, and reputationally, because when companies hit near-death experiences, mercenaries update LinkedIn whilst founders dig in and pivot.

• Team alignment on exit magnitude determines whether you reach venture scale. Investors assess whether founders will turn down early exits to build fund-returning assets, seeking partners obsessed with changing the standard of care globally rather than securing personal safety nets.

---

The Foundation: Technical Mastery Meets Commercial Logic

Founders come in many forms, yet in MedTech, the foundation almost always begins with a specific pillar of expertise. The early phases are typically driven by a technical founder, often an engineer or physician with unique clinical insight, or a prior exited founder applying a proven operational playbook to a new problem. These individuals provide the initial spark, whether through a defensible technological moat or deep understanding of the economics of risk.

Technical enthusiasm or past success alone won't secure institutional capital for the long haul. To transform an invention into a viable business, the founding team must evolve. A sophisticated winning capability requires a succinct story that combines clinical, technical, and commercial expertise. The technical lead ensures the IP landscape is protected and the product works. A business partner navigates complex market landscapes and translates scientific data into realistic exit strategies. Both are essential.

This balance is critical because MedTech companies don't typically scale by selling directly to consumers. They scale by reaching value inflection points that make them attractive to global strategic partners. A purely technical team might focus solely on product efficacy. A commercially balanced team understands they're building an asset for acquisition.

The Inner Circle: Curating Alignment Across the Board

Surrounding the core team with the right extended leadership through executives, board members, and key advisors represents the next step in building leverage. The quality of this circle is defined strictly by alignment.

Alignment doesn't mean uniformity. A healthy board and advisory circle should offer diverse opinions. Friction in the form of rigorous debate often drives the best strategic results and prevents groupthink. There's a sharp distinction, however, between productive debate and misaligned commitment. When conflict stems from personal agendas or lack of engagement, it drains energy and requires immediate correction.

Founders must remain vigilant against specific behaviours that dilute focus. Watch for the self-interested networker who uses your company primarily to expand their own network or access your investor list for future deal flow. The passive passenger provides input only when prompted, offering warm body presence rather than building solutions before you ask. The misaligned clock operates on a timeline that conflicts with the company's reality, pushing for premature liquidity or holding out for unrealistic valuations. Each of these patterns signals a relationship that consumes more value than it creates.

The Conviction Test: Founders vs. Hired Guns

One of the most significant risks for early-stage investors is a team that has been dressed up for fundraising. This occurs when a company hires polished executives with impressive resumes but no real skin in the game to create the illusion of maturity.

Winning teams come in all forms, but there's no substitute for founders who have been there from day one. Investors look for leaders who are all in financially, emotionally, and reputationally.

The warning signs appear quickly. The mercenary executive, hired as CEO or COO and incentivised primarily by cash salaries rather than equity, views the venture as a job, not a mission. When the company hits a near-death experience, these leaders often update their LinkedIn profiles and leave. Founders dig in and pivot.

The fractional leader runs two other companies on the side, signalling they're hedging their bets. Investors need to know that the pilot of the plane isn't parachuting out if the engine sputters. Then there's the resume padder, brought in solely to add logos of big corporates to the pitch deck. Perhaps they're listed as an Ex-Medtronic VP, but they lack the grit required for early-stage chaos.

Hired executives are valuable, but timing is everything. They belong in later stages or commercialisation when the risk profile shifts from existential questions about whether it will work to operational questions about whether you can scale sales. At that stage, you need the specific playbook of a seasoned professional.

In the early building phase, a polished resume isn't enough. You need a convicted leader, someone whose belief in the mission is absolute. This leader views the venture not as a career step but as a personal mandate to succeed. This depth of conviction is the only thing that sustains a team through the inevitable setbacks of the early years.

Alignment on the Big League Exit

The team must be aligned on the magnitude of the outcome. MedTech is a high-risk, high-reward asset class. Investors are looking for companies built to play in the big leagues, targets for major strategic acquirers that return the fund/

This creates potential friction with founders, particularly first-time founders. Running a startup is gruelling. It's understandable that a founder facing burnout might be tempted by a twenty million dollar offer that provides personal financial stability, life-changing money for an individual.

Venture capitalists require fund-returning money. They need founders with the stamina and ambition to turn down the early, easy exit to build the five hundred million dollar plus category-defining asset.

Investors assess this early on. They look for founders who aren't just seeking a quick flip to escape the hardship, but who are obsessed with the problem and committed to the maximum potential of the technology. They want partners ready to go the distance, knowing that the real victory is changing the standard of care globally, not just securing a safety net.

Building the Resilient Engine

A successful MedTech team is defined by its ability to execute. It requires technical skill to build a moat, business acumen to validate the market, and strategic foresight to design for an exit. When you combine these elements with a culture of conviction, you move beyond the churn of survival. You build a resilient engine capable of reaching the only finish line that matters: a successful exit that changes the standard of care.

---

If you're navigating the fundraising process and need guidance on financial strategy, investor preparation, or operational planning, connect with our team to explore how operator-led experience can support your path to market success.

CFO's Playbook: Funding Tips for New MedTech Founders

• Securing venture capital represents far more than landing funding.
  The fundraising process is a rigorous operational stress test that reveals the strength of your business model, the discipline of your financial projections, and the clarity of your path to value inflection.

• MedTech companies face fundamentally different challenges than software ventures.
  Lengthy clinical validation, binary regulatory outcomes, significant capital needs before revenue, and complex IP landscapes demand a financial strategy that genuinely understands these operational realities.

• Financial model rigour reveals capability more clearly than marketing materials.
  A strong financial plan demonstrates expertise through detailed R&D schedules, realistic burn rates, clear milestone-based valuations, and the ability to support the company through multiple, defined funding rounds.

• Due diligence preparation determines value beyond capital.
  Having a data room ready with clean IP filings, organised clinical data, detailed regulatory strategy documents, and clear corporate governance accelerates the process and builds immediate investor trust.

• Timeline alignment prevents destructive pressure on your strategy.
  MedTech development requires patience and realistic expectations about clinical data readouts, regulatory clearance periods, and exit horizons.

---

Reframing Fundraising as an Operational Stress Test

Securing investors represents a critical milestone for MedTech startups, but the process of raising capital itself carries far greater consequences than simply landing funding. Your fundraising strategy is an operational stress test that forces internal clarity, influences strategic decisions, and either accelerates or hinders your path to market success.

Unlike traditional software ventures, MedTech companies face unique complexities. Navigating clinical trial costs, managing significant capital needs, executing multi-year milestone-driven development, and operating within sophisticated competitive landscapes demand founders genuinely understand the economics of risk. The regulatory pathway alone can consume years and millions in capital before generating a single dollar of revenue.

This process demands rigorous evaluation beyond pitch deck excitement. The financial model you establish now will likely govern cash flow for years. Understanding how to model runway, prepare for diligence, and communicate your value inflection points proves essential for founders building investor confidence and maintaining strategic control.

Evaluating Your Financial Model and Runway Rigour

Your financial model provides concrete evidence of business capability that high-level slides cannot replicate. A strong plan demonstrates successful navigation of the valley of death through realistic projections that investors can stress-test and validate.

The R&D burn rate requires detailed month-by-month expense breakdowns tied to specific, achievable milestones. Locking data for a pivotal clinical trial or achieving Proof-of-Concept completion represents the kind of concrete checkpoint that sophisticated investors evaluate. Contingency planning matters equally, with precise schedules for managing unexpected costs related to regulatory changes or clinical enrolment delays built into your assumptions.

Runway calculations must clearly articulate how many months of operation your current or target raise provides, tied directly to a major value inflection point. FDA clearance or a critical clinical readout represents the kind of binary outcome that either validates your thesis or forces strategic reassessment. Investors evaluate whether you've built sufficient buffer to reach that milestone without requiring emergency bridge rounds that destroy valuation.

Critical questions reveal depth of preparation quickly. Is the model built bottom-up from actual vendor quotes and CRO contracts, or top-down from industry averages? How does a six-month regulatory delay impact your cash flow and subsequent valuation? What specific assumptions underlie your cost of goods sold at commercial scale? Vague responses or inability to provide data-backed expense drivers signal limited operational rigour.

Investors don't buy the best-case scenario. They invest in the model that clearly articulates the necessary resources and timelines for the most likely outcome, whilst quantifying the downside risk that could force difficult decisions.

Deep Diligence and Tactical Execution

Deep diligence preparation distinguishes valuable founders from hopeful entrepreneurs. Investors need to de-risk their investment, and the founder's job is to make that process effortless. Truly sophisticated founders go one step further by anticipating and drafting the VC's final investment document before being asked.

Preparing an actual draft Investment Memo summarising the key areas that VC funds document internally forces you to adopt the investor's perspective. This document should succinctly cover deal rationale, team credentials, market opportunity, due diligence findings on IP and regulatory strategy, financial projections with MOIC and return profile, plus key risks with specific mitigants. Submitting this alongside your pitch deck immediately elevates your credibility and signals operational maturity.

The organised, accessible virtual data room should exist from day one, not assembled frantically when term sheets arrive. Financials including historicals, budget versus actuals, and the detailed version-controlled pro-forma financial model form the foundation. Intellectual property documentation with clean patent applications, freedom-to-operate analyses, and invention disclosures proves you've protected your competitive position.

Corporate governance materials including articles of incorporation, capitalisation table, and past board minutes demonstrate professional structure. Clinical and regulatory documentation with detailed study protocols, interim data, and core regulatory strategy documents covering pathway selection justification and QMS status show you understand the approval process intimately.

Access to clean documentation accelerates the investment timeline and signals organisational discipline. When a potential investor's team needs confirmation on patent claims or the regulatory timeline, established documentation makes the difference between weeks and months of negotiation time. Every day saved in diligence preserves runway and maintains momentum.

Practical Skills for Fundraising Success

Fundraising is a full-time, high-contact sales process that demands aggressive and proactive strategy. Starting early and maintaining momentum separates successful raises from desperate scrambles.

Timing determines leverage. Initiating fundraising at least twelve to eighteen months before your current cash runway expires provides negotiating room and prevents the appearance of desperation. The diligence and closing process can stretch longer than founders anticipate, and pitching with only a few months of runway remaining signals poor planning to sophisticated investors.

Starting with your friends and family network allows you to refine your message and gather initial feedback before approaching institutional investors. This prototype pitching process reveals which elements resonate and which arguments fall flat, allowing iterative improvement before the stakes increase. The key principle remains simple: keep pitching and keep asking for funding. If you don't ask, you won't receive. Track your conversations like a sales pipeline with clear stages and follow-up actions.

Always end meetings, even rejections, by asking for referrals to other investors who might be a better fit. This practice transforms closed doors into potential introductions whilst demonstrating persistence and professionalism that investors remember.

Research drives targeting effectiveness. Never cold-pitch without understanding whether investors actually fund your specific MedTech space, whether medical devices, digital health diagnostics, or surgical robotics. Identifying investor prototypes who show interest in your deal creates a searchable pattern. Are they family offices, high-net-worth individuals, physicians specialising in your clinical area, or founders who have exited MedTech companies? Once you gain traction with a certain prototype, such as orthopaedic surgeons in your region, continue searching out a larger pool of such investors and requesting introductions within this niche space.

Pitch and diligence readiness requires constant preparation. Have your deck, your data room, and a strong pitch refined through practice ready at all times. Be prepared to answer the questions that determine investment conviction with specificity and confidence.

Your unique value proposition must articulate why you're differentiated with a defensible technological moat or clinical advantage that competitors cannot easily replicate. The path to success should detail the achievable milestone sequence that leads to market adoption, not vague aspirations about future scale. Risk mitigation requires honest assessment of what risks exist for investors and how you're systematically de-risking regulatory, reimbursement, or technical uncertainties through your development plan.

IP strategy deserves clear articulation. Is your intellectual property filed, and what protection strategy governs your approach? Do you have freedom-to-operate clearance in your key markets, or does patent landscape analysis reveal potential conflicts requiring resolution? Team strength requires a succinct story explaining why this specific combination of clinical, technical, and commercial expertise creates a winning capability.

Investor return expectations must connect to a realistic exit strategy. Have you thought through acquisition scenarios by strategic partners and the potential Multiple on Invested Capital that makes your opportunity compelling? MedTech exits follow patterns, and understanding how your company fits established acquisition theses demonstrates commercial awareness beyond technical enthusiasm.

---

Fundraising Preparedness Checklist

Before initiating investor outreach, evaluate your readiness across these fundamental areas:

Financial Model Completeness

• Bottom-up R&D burn rate with month-by-month breakdown tied to specific milestones

• Contingency budget for regulatory delays and clinical enrolment challenges

• Clear runway calculation showing months to next value inflection point

• COGS assumptions based on actual vendor quotes, not industry averages

• Detailed CRO contracts or specific cost estimates for clinical trials

Due Diligence Data Room

• Historical financials and budget versus actuals analysis

• Version-controlled pro-forma financial model

• Clean patent applications with freedom-to-operate analyses

• Articles of incorporation and current capitalisation table

• Board minutes and corporate governance documentation

• Detailed clinical study protocols and interim data

• Regulatory strategy documents including pathway selection justification and QMS status

Pitch Materials and Strategy

• Draft Investment Memo covering deal rationale, team, market opportunity, DD findings, financial projections, and risk mitigants

• Refined pitch deck tested with friends and family network

• Investor pipeline tracked like a sales process

• Targeted list of investors active in your specific MedTech space

• Identified investor prototypes showing interest patterns

Key Questions Preparation

• Articulated unique value proposition and defensible moat

• Achievable milestone sequence leading to market adoption

• Specific risk mitigation strategies for regulatory, reimbursement, and technical uncertainties

• Clear IP protection strategy with FTO clearance status

• Succinct team story highlighting clinical, technical, and commercial expertise

• Realistic exit strategy connecting to potential MOIC for investors

---

If you're navigating the fundraising process and need guidance on financial strategy, investor preparation, or operational planning, connect with our team to explore how operator-led experience can support your path to market success.